Needham分析师Serge Belanger维持买入评级，并将目标价从30美元上调至38美元。 On Sep 11, major Wall Street analysts update their ratings for $Viridian Therapeutics (VRDN.US)$, with price targets ranging from $27 to $56.
Wells Fargo analyst Derek Archila maintains with a buy rating, and maintains the target price at $37.
Oppenheimer analyst Leland Gershell maintains with a buy rating, and maintains the target price at $28.
Needham analyst Serge Belanger maintains with a buy rating, and adjusts the target price from $30 to $38.
Stifel analyst Alex Thompson CFA maintains with a buy rating, and adjusts the target price from $33 to $40.
BTIG analyst Julian Harrison maintains with a buy rating, and adjusts the target price from $46 to $56.
Here are the latest investment ratings and price targets for $Viridian Therapeutics (VRDN.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
